Member Info for grizzlyb

Exactly - if we're all well aware of and understand any negatives, in my view, it strengthens the positives.

RENE_to_40p, if you watch the video I posted below, Michael Hunt has said they won't need a huge amount of cash to get BOTH products to market.

I'm fairly confident that if they get one to market, they'll be able to fund the other.

Approximately 50% of the current market cap is cash.

Michael Hunt:

https://youtu.be/NsKp92xLzVI

https://www.bbc.co.uk/news/business-50052945

5002 must be loving loving life with +20 letters in the untreated eye as well.

It's difficult to assess the results when comparing to baseline, but not being given the baseline figure for each subject.

In my view Woodford didn't buy 30% here to sell on a licence deal, he bought to sell on a takeover. For as long as that remains a distinct possibility, I see no reason why he'd sell any considerable amount.

Subjects 1 and 2 had the lowest baseline at 9 letters.

Subject 3 baseline was 32 letters.

Subjects 4 to 12 baselines will be between 36 and 63 letters.

It's clear that subject 1 dropped off towards 9 months, but still a 13 letter difference between treated and untreated, and if the treatment interval is to be 12-monthly I would expect a drop-off towards the next intervention.

Treeshakers, further to your previous question regarding ReNeuron's competitive advantage over jCyte, Olav Hellebø mentioned in an ARM Investor Day interview earlier this year that ReNeuron's key patent is for the reduced oxygen culture of the cryopreserved cells. I'm not sure how jCyte are faring on this front.

As an aside, the FDA 15 letter gain guideline for gene therapy may be reflective of the considerable cost of treatment. For ReNeuron's cell-based therapy, with a considerably lower cost of treatment, a product with a lesser letter gain may still be highly viable.

Dr Dugel, our principal investigator, is also principal investigator of the Beovu HAWK trial. A positive update from him next weekend will certainly carry considerable weight.

Note, 15 letter improvement in 30% of patients at 12 months in their wet AMD trial.

Treeshakers:

• jCyte's cells are administered intravitreally, so marginally less invasive
• ReNeuron's cells are administered sub-retinally

• jCyte's mean difference in visual acuity between treated and untreated eyes at their highest dose (3 million cells) was 9 letters at 12 months post-treatment
• ReNeuron's highest dose (1 million cells) is 13 letters at 9 months (one patient).

There are certainly similarities. Further trial data will be key.

For anybody that hasn't seen it, see below link for Jason Comander's previous presentstion including Phase 1 and early 2a data.

http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/Jason-Commander-gene-stem-cell-conference-April-2019.pdf

Taverham, to me it looks like one of cohort 1 or 2, (i.e. within the first 6 patients) and one of cohorts 1, 2 or 3 (i.e. within the first 8 patients).

optomdad, when I contacted Woodford a few months ago they were very positive about ReNeuron, so I wouldn't assume they'll be dumping their entire holding.

Clinically meaningful improvement, but let's not forget that even slowing down the rate of degradation would be a significant benefit to the patients.

jCyte's phase 1/2a RP study demonstrated a mean difference of 9 letters between the treated and untreated eye at 12 months at the highest dose.

At 9 months (and one patient) ReNeuron are at 13 letters [+ 12 (treated) to - 1 (untreated)].

jCyte reported 'no grade 4 events associated with the treatment', but didn't exclude grade 3 adverse events. For reference, grade 3 is severe, grade 4 is life-threatening.

It's also worth noting that there was a severe, i.e. grade 3, adverse effect in both Spark's Luxterna Phase I and Phase III trials, albeit with a larger population. Luxterna demonstrated a mean 8 letter improvement, averaged across both treated eyes, at 3 years.

https://www.meetingonthemesa.com/company-presentations/#reneuron

I missed the start, he was talking about RP when I started to watch. I expect you'll find it on Youtube within a day or two.

Michael Hunt has just presented at the Meeting on the Mesa, he didn't go into much detail though and no questions asked which is frustrating. Tge trip seems a bit excessive for a few minutes of talking and no real updates.

For anybody that would prefer to hear MH speak, pop along to the Shares Magazine investor evening on the 10th - he's presenting again.

https://www.evaluate.com/vantage/articles/news/trial-results/reneurons-reinvention-falters

Wigwammer, me at 10:18 ;)

'3 patients out of 4 have SIGNIFICANT improvement at 6 months.

6 patients out of 8 have VERY GOOD improvement at 3 months.'

But, as mentioned by somebody on here earlier today, patient 1 hasn't maintained the full improvement at 9 months (baseline = 9 letters, 2 months = 29 letters, 4 months = 30 letters, 9 months = 21 letters).

I'd really like to see patient by patient data.

And those privy to the leak were buying...